

PATENT COOPERATION TREATY
INTERNATIONAL PRELIMINARY EXAMINATION REPORT

IDENTIFICATION OF THE INTERNATIONAL APPLICATION		Applicant's or Agent's File Reference PP/8620																						
International Application No. PCT/GB91/00212	International Filing Date 13 February 1991 (13.02.91)																							
Receiving Office UK PATENT OFFICE	Priority Date Claimed 13 February 1990 (13.02.90)																							
Applicant (Name) AMERSHAM INTERNATIONAL PLC ET AL																								
BASIS OF REPORT																								
<p>1. AMENDMENTS AND/OR RECTIFICATIONS¹ — The amendments and/or rectifications made before this International Preliminary Examining Authority in respect of the claims, the description, and/or drawings in the above-identified international application are annexed to this report.</p> <p>a. <input checked="" type="checkbox"/> This report has been established on the basis of the following application documents:</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;"><input checked="" type="checkbox"/></td> <td style="width: 85%;">the application documents as filed</td> </tr> <tr> <td><input type="checkbox"/></td> <td>description, pages _____ as originally filed</td> </tr> <tr> <td></td> <td>description, pages _____ filed with your letter of _____</td> </tr> <tr> <td></td> <td>description, pages _____ filed with your letter of _____</td> </tr> <tr> <td></td> <td>description, pages _____ filed with your letter of _____</td> </tr> <tr> <td><input type="checkbox"/></td> <td>claim(s) _____ as originally filed</td> </tr> <tr> <td></td> <td>claim(s) _____ filed with your letter of _____</td> </tr> <tr> <td></td> <td>claim(s) _____ filed with your letter of _____</td> </tr> <tr> <td></td> <td>claim(s) _____ filed with your letter of _____</td> </tr> <tr> <td><input type="checkbox"/></td> <td>drawings, sheet/fig. _____ as originally filed</td> </tr> <tr> <td></td> <td>drawings, sheet/fig. _____ filed with your letter of _____</td> </tr> </table> <p>b. <input type="checkbox"/> The amendments resulted in the cancellation of the following sheets:</p> <p>c. <input type="checkbox"/> This report has been established as if the amendments indicated on the extra sheet have not been made, since, for the reasons indicated, they have been considered to go beyond the disclosure as filed.</p>			<input checked="" type="checkbox"/>	the application documents as filed	<input type="checkbox"/>	description, pages _____ as originally filed		description, pages _____ filed with your letter of _____		description, pages _____ filed with your letter of _____		description, pages _____ filed with your letter of _____	<input type="checkbox"/>	claim(s) _____ as originally filed		claim(s) _____ filed with your letter of _____		claim(s) _____ filed with your letter of _____		claim(s) _____ filed with your letter of _____	<input type="checkbox"/>	drawings, sheet/fig. _____ as originally filed		drawings, sheet/fig. _____ filed with your letter of _____
<input checked="" type="checkbox"/>	the application documents as filed																							
<input type="checkbox"/>	description, pages _____ as originally filed																							
	description, pages _____ filed with your letter of _____																							
	description, pages _____ filed with your letter of _____																							
	description, pages _____ filed with your letter of _____																							
<input type="checkbox"/>	claim(s) _____ as originally filed																							
	claim(s) _____ filed with your letter of _____																							
	claim(s) _____ filed with your letter of _____																							
	claim(s) _____ filed with your letter of _____																							
<input type="checkbox"/>	drawings, sheet/fig. _____ as originally filed																							
	drawings, sheet/fig. _____ filed with your letter of _____																							
<p>2. PRIORITY</p> <p>a. <input type="checkbox"/> This report has been established as if no priority has been claimed due to the failure to furnish within the prescribed time limit the requested:</p> <p><input type="checkbox"/> copy of the earlier application whose priority has been claimed.</p> <p><input type="checkbox"/> translation of the earlier application whose priority has been claimed.</p> <p>b. <input type="checkbox"/> This report has been established as if no priority has been claimed due to the fact that the priority claim has been found invalid.</p> <p>Thus, for the purposes of this report, the international filing date indicated above is considered to be the relevant date.</p>																								
<p>* Where replacement sheets are annexed to this report, a translation of these replacement sheets must be furnished to the elected Offices within the time limit applicable under PCT Article 39(1).</p>																								

BASIS OF REPORT (Continued)**3. UNITY OF INVENTION³ — The international application does not comply with the requirement of unity of invention.****a. In response to an invitation to restrict or pay additional fees the applicant has:**

- restricted the claims.
 paid additional fees.
 paid additional fees under protest. Where requested by the applicant, the text of the protest together with the decision taken thereon are annexed to this report.
 neither restricted nor paid additional fees.

b. No invitation has been issued. The opinion of this International Preliminary Examining Authority is that the international application does not comply with the requirement of unity of invention for the following reasons. (specify)

c. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- all parts.
 the parts relating to the restricted claims, that is claims Nos. _____.
 the parts relating to the main invention, that is claims Nos. _____.

4. NON-ESTABLISHMENT OF REPORT ON QUESTIONS OF NOVELTY, INVENTIVE STEP OR INDUSTRIAL APPLICABILITY⁴

The questions of whether the claimed invention appears to be novel, to involve an inventive step or to be industrially applicable have not for the reasons indicated been gone into in respect of:

a. the entire international application

b. claims Nos. _____

for the following reasons:

Said international application, or said claims Nos. _____ relate to the following subject matter which does not require an international preliminary examination. (specify)

The description, claims, or drawings (indicate particular elements) or said claims Nos. _____ are so unclear that no meaningful opinion could be formed.

The claims, or said claims Nos. _____ are so inadequately supported by the description that no meaningful opinion could be formed.

Said claims Nos. _____ are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all.)⁸

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵ B03C 1/00: C07K 3/24: 3/28: C12N 1/02. 7/02. 5/00**REASONED STATEMENT AS TO CLAIMS MEETING CRITERIA OF NOVELTY (N), INVENTIVE STEP (IS)
AND INDUSTRIAL APPLICABILITY (IA)⁶ AND CITATIONS⁷ AND EXPLANATIONS⁸
SUPPORTING SUCH STATEMENT**

CLAIM NUMBER	STATEMENT (CRITERIA)	CITATIONS AND EXPLANATIONS
1-12	YES (N, IS, IA)	<p>All claims meet the requirements of industrial applicability, novelty and inventive step.</p> <p>They are distinguished from the documents cited by the International Searching Authority in that there is no disclosure of the suspension of magnetic particles in a polymer solution prior to precipitating the polymer out of the solution.</p>

NON-WRITTEN DISCLOSURES *

Kind of Non-Written Disclosure	Date of Written Disclosure referring to the Non-Written Disclosure	Date of Non-Written Disclosure

CERTAIN PUBLISHED DOCUMENTS **

Application/Patent	Date of Publication	Filing Date	Priority Date (Valid Claim)

CERTAIN DEFECTS IN THE INTERNATIONAL APPLICATION ***

The following defects in the form or contents of the international application have been noted.


The claims are not in two part form as required by Rule 6.3(b).

CERTAIN OBSERVATIONS ON THE INTERNATIONAL APPLICATION ****

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description have been noted.

The contents of the Agent's letter dated 10 September 1991 have been considered.

CERTIFICATION

Date Demand Submitted 10 September 1991 / 10.09.01	Date of Completion of the International Preliminary Examination Report 12 February 1992 / 12.02.92
International Preliminary Examining Authority THE PATENT OFFICE CARDIFF RD., NEWPORT GWENT NP9 1RH	Signature of Authorized Officer J L FREEMAN 

**INTERNATIONAL APPLICATION
UNDER THE
PATENT COOPERATION TREATY
REQUEST**

THE UNDERSIGNED REQUESTS THAT THE PRESENT
INTERNATIONAL APPLICATION BE PROCESSED
ACCORDING TO THE PATENT COOPERATION TREATY

(The following is to be checked by the receiving Office)

**INTERNATIONAL
APPLICATION No.:**

PCT/GB 91/00212

**INTERNATIONAL
FILING DATE:**

13 February 1991
13-2-91

**United Kingdom Patent Office
PCT International Application**
(Stamp)
Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference
(indicated by applicant if desired)

PP/8620

Box No. I TITLE OF INVENTION

PRECIPITATING POLYMERS

Box No. II APPLICANT (WHETHER OR NOT ALSO INVENTOR); DESIGNATED STATES FOR WHICH HE/SHE/IT IS APPLICANT. Use this box for indicating the applicant or, if there are several applicants, one of them. If more than one person (includes, where applicable, a legal entity) is involved, continue in Box No. III.

The person identified in this box is (mark one check-box only):

applicant and
inventor*

applicant
only

Name and address: ** AMERSHAM INTERNATIONAL PLC
Amersham Place
Little Chalfont
Buckinghamshire
HP7 9NA
ENGLAND G.B.

Telephone number (including area code): | Telegraphic address:

| Teleprinter address:

State of nationality: G.B.

State of residence: G.B.

The person identified in this box is *applicant* for the purposes of (mark one check-box only):

all designated
States

all designated States except
the United States of America

the United States
of America only

the States indicated
in the "Supplemental Box"

Box No. III FURTHER APPLICANTS, IF ANY; (FURTHER) INVENTORS, IF ANY; DESIGNATED STATES FOR WHICH THEY ARE APPLICANTS (IF APPLICABLE). A separate sub-box has to be filled in in respect of each person (includes, where applicable, a legal entity). If the following two sub-boxes are insufficient, continue in the "Supplemental Box," (giving there for each additional person the same indications as those requested in the following two sub-boxes) or by using a "continuation sheet."

The person identified in this sub-box is (mark one check-box only):

applicant and
inventor*

applicant
only

inventor
only

Name and address: ** REEVE, MICHAEL ALAN
149 Grays Road
Henley-on-Thames
RG9 1TE
ENGLAND G.B.

If the person identified in this sub-box is *applicant* (or *applicant and inventor*), indicate also:

State of nationality: G.B.

State of residence: G.B.

and whether that person is *applicant* for the purposes of (mark one check-box only):

all designated
States

all designated States except
the United States of America

the United States
of America only

the States indicated
in the "Supplemental Box"

The person identified in this sub-box is (mark one check-box only):

applicant and
inventor*

applicant
only

inventor
only*

Name and address: **

If the person identified in this sub-box is *applicant* (or *applicant and inventor*), indicate also:

State of nationality:

State of residence:

and whether that person is *applicant* for the purposes of (mark one check-box only):

all designated
States

all designated States except
the United States of America

the United States
of America only

the States indicated
in the "Supplemental Box"

- * If the person indicated as "applicant and inventor" or as "inventor only" is not an *inventor* for the purposes of all the designated States, give the necessary indications in the "Supplemental Box."
- ** Indicate the name of a natural person by giving his/her family name first followed by the given name(s). Indicate the name of a legal entity by its full official designation. In the address, include both the postal code (if any) and the State (name).
- *** If residence is not indicated, it will be assumed that the State of residence is the same as the State indicated in the address

L No. IV AGENT (IF ANY) OR COMMON REPRESENTATIVE (IF ANY): ADDRESS FOR NOTIFICATIONS (IN CERTAIN CASES). A common representative may be appointed only if there are several applicants and if no agent is or has been appointed; the common representative must be one of the applicants.
The following person (includes, where applicable, a legal entity) is hereby/has been appointed as agent or common representative to act on behalf of the applicant(s) before the competent International Authorities:

Name and address, including postal code and country:

If the space below is used instead for an address for notifications, mark here: _____

PENNANT, PYERS
Stevens, Hewlett & Perkins
* 5 Quality Court
Chancery Lane
LONDON WC2A 1HZ G.B.

* 1B
CHANGE
OF ADDRESS
SEE #12

Telephone number (including area code):
071-405-8393

Telegraphic address:

Teleprinter address:
071-430-2262

Box No. V DESIGNATION OF GROUPS OF STATES OR STATES⁽¹⁾: CHOICE OF CERTAIN KINDS OF PROTECTION OR TREATMENT. The following designations are hereby made (please mark the applicable check-boxes):

Regional Patent

- EP European Patent⁽²⁾: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, DE Germany, DK Denmark, ES Spain, FR France, GB United Kingdom, GR Greece, IT Italy, LU Luxembourg, NL Netherlands, SE Sweden,
and any other State which is a Contracting State of the European Patent Convention and of the PCT
- OA OAPI Patent: Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Congo, Gabon, Mali, Mauritania, Senegal, Togo,
and any other State which is a Contracting State of OAPI and of the PCT; if other OAPI title desired, specify on dotted line⁽³⁾:

National Patent (if other kind of protection or treatment desired, specify on dotted line⁽³⁾)

- | | |
|--|--|
| <input type="checkbox"/> AT Austria ⁽³⁾ | <input type="checkbox"/> KR Republic of Korea ⁽³⁾ |
| <input type="checkbox"/> AU Australia ⁽³⁾ | <input type="checkbox"/> LK Sri Lanka |
| <input type="checkbox"/> BB Barbados | <input type="checkbox"/> LU Luxembourg ⁽³⁾ |
| <input type="checkbox"/> BG Bulgaria ⁽³⁾ | <input type="checkbox"/> MC Monaco ⁽³⁾ |
| <input type="checkbox"/> BR Brazil ⁽³⁾ | <input type="checkbox"/> MG Madagascar |
| <input checked="" type="checkbox"/> CA Canada | <input type="checkbox"/> MW Malawi ⁽³⁾ |
| <input type="checkbox"/> CH and LI Switzerland and Liechtenstein | <input type="checkbox"/> NL Netherlands |
| <input type="checkbox"/> DE Germany ⁽³⁾ | <input type="checkbox"/> NO Norway |
| <input type="checkbox"/> DK Denmark | <input type="checkbox"/> PL Poland ⁽³⁾ |
| <input type="checkbox"/> ES Spain ⁽³⁾ | <input type="checkbox"/> RO Romania |
| <input type="checkbox"/> FI Finland | <input type="checkbox"/> SD Sudan |
| <input type="checkbox"/> GB United Kingdom | <input type="checkbox"/> SE Sweden |
| <input type="checkbox"/> HU Hungary | <input type="checkbox"/> SU Soviet Union ⁽³⁾ |
| <input checked="" type="checkbox"/> JP Japan ⁽³⁾ | <input checked="" type="checkbox"/> US United States of America ⁽³⁾ |
| <input type="checkbox"/> KP Democratic People's Republic of Korea ⁽³⁾ | |

Space reserved for designating States (for the purposes of a national patent) which have become party to the PCT after the issuance of this sheet:

- (1) The applicant's choice of the order of designations may be indicated by marking the check-boxes with sequential arabic numerals (see also the "Notes to Box No. V").
 (2) The selection of particular States for a European patent can be made upon entering the national (regional) phase before the European Patent Office (see also the "Notes to Box No. V").
 (3) If another kind of protection or a title of addition or, in the United States of America, treatment as a continuation or a continuation-in-part is desired, specify according to the instructions given in the "Notes to Box No. V".

No. VI PRIORITY CLAIM (IF ANY). The priority of the following earlier application(s) is hereby claimed:

Country (country in which it was filed if national application; one of the countries for which it was filed if regional or international application)	Filing Date (day, month, year)	Application No.	Office of filing (fill in only if the earlier application is an international application or a regional application)
(1) G.B.	13 February 1990 13 - 2 - 1990	90 03 253.3	
(2)			
(3)			

(Letter codes may be used to indicate country and/or Office of filing)

When the earlier application was filed with the Office which, for the purposes of the present international application, is the receiving Office, the applicant may, *against payment of the required fee*, ask the following:

the receiving Office is hereby requested to prepare and transmit to the International Bureau a certified copy of the above-mentioned earlier application/of the earlier applications identified above by the numbers (insert the applicable numbers)

Box No. VII EARLIER SEARCH (IF ANY). Fill in where a search (international, international-type or other) by the International Searching Authority has already been requested (or completed) and the said Authority is now requested to base the international search, to the extent possible, on the results of the said earlier search. Identify such search or request either by reference to the relevant application (or the translation thereof) or by reference to the search request.

International application number or number and country (or regional Office) of other application:

90 03 253.3

International/regional/national filing date: 13 February 1990

Date of request for search:

27 February 1990

Number (if available) given to search request: RS 85977 GB

Box No. VIII SIGNATURE OF APPLICANT(S) OR AGENT

PENNANT, PYERS

If the present Request form is signed on behalf of any applicant by an agent, a separate power of attorney appointing the agent and signed by the applicant is required. If in such case it is desired to make use of a general power of attorney (deposited with the receiving Office), a copy thereof must be attached to this form.

Box No. IX CHECK LIST (To be filled in by the Applicant)

This international application contains the following number of sheets:

1. request	3	sheets
2. description	16	sheets
3. claims	3	sheets
4. abstract	1	sheets
5. drawings	4	sheets
Total		27 sheets

Figure number of the drawings (if any) is suggested to accompany the abstract for publication.

This international application as filed is accompanied by the items marked below:

1. separate signed power of attorney
2. copy of general power of attorney
3. priority document(s) (see Box No. VI)
4. receipt of the fees paid or revenue stamps
5. cheque for the payment of fees
6. request to charge deposit account
7. other document (specify) Patents Form 24/77, cheque for £12; Earlier search report.

(The following is to be filled in by the receiving Office)

1. Date of actual receipt of the purported international application: 13 February 1991 13-2-91
2. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:
3. Date of timely receipt of the required corrections under Article 11 of the PCT:
4. Drawings Received No Drawings.

(The following is to be filled in by the International Bureau)

Date of receipt of the record copy:

05 MARCH 1991 (05.03.91)

See notes on accompanying sheet

**PATENT COOPERATION TREATY
INTERNATIONAL SEARCH REPORT**

IDENTIFICATION OF INTERNATIONAL APPLICATION		Applicant's or Agent's File Reference PP/8620
International Application No. PCT/GB 91/00212	International Filing Date 13th February 1991	
Receiving Office RO/GB	Priority Date Claimed 13th February 1990	
Applicant AMERSHAM INTERNATIONAL PLC et al.		
I. <input type="checkbox"/> CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹ (Observations on supplemental sheet (2))		
II. <input type="checkbox"/> UNITY OF INVENTION IS LACKING ² (Observations on supplemental sheet (2))		
III. TITLE, ABSTRACT AND FIGURE OF DRAWING		
1. The following indicated items are approved as submitted by the applicant: ³ <input type="checkbox"/> Title. <input checked="" type="checkbox"/> Abstract.		
2. The texts established by this International Searching Authority of the following indicated items are set forth below: <input checked="" type="checkbox"/> Title. <input type="checkbox"/> Abstract.		
<p>Method to isolate macromolecules using magnetically attractable beads which do not specifically bind the macromolecules.</p>		
<input type="checkbox"/> Text of the abstract continued on supplemental sheet (1)		
3. a. <input type="checkbox"/> The definitive contents of the abstract are established by this International Searching Authority as proposed in form PCT/ISA/204 previously sent to the applicant.		
b. <input type="checkbox"/> This report is incomplete as far as the abstract is concerned as the time limit for comments by the applicant on the draft prepared by this International Searching Authority has not expired. ⁴		
4. Figure to be published with the abstract: ⁵ Figure No. <u>1a</u> <input type="checkbox"/> None of the figures		
<input type="checkbox"/> as suggested by the applicant <input checked="" type="checkbox"/> because the applicant failed to suggest a figure <input type="checkbox"/> because this figure better characterizes the invention		

INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 91/00212

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵: B 03 C 1/00, C 07 K 3/24, 3/28, C 12 N 1/02, 7/02, 5/00

II. FIELDS SEARCHED

Minimum Documentation Searched ⁷

Classification System	Classification Symbols
IPC ⁵	B 03 C, C 07 K, C 12 N

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

III. DOCUMENTS CONSIDERED TO BE RELEVANT*

Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP, A, 0162819 (PERO et al.) 27 November 1985 see the whole document; in particular page 2, line 25 - page 4, line 31 --	1-4,6-8
X	US, A, 4001197 (MITCHELL et al.) 4 January 1977 see the whole document; especially figure 1; columns 6-8, claims --	1-4,6-8,12
X	US, A, 3470067 (WARREN et al.) 30 September 1969 see the whole document; especially columns 1,2, summary; column 8, claims --	1-4,6-8
X	BE, A, 686243 (PFIZER) 28 February 1967 see the whole document, especially pages 7-8, examples 1,2; pages 14-15, claims --	1-4,6-8
		. / .

* Special categories of cited documents: ¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"g." document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

20th May 1991

Date of Mailing of this International Search Report

- 8.07.91

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

M. PEIS

M. Peis

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	WO, A, 8401503 (COULTER et al.) 26 April 1984 see the whole document; especially page 7, lines 1-5	1-12
A	EP, A, 0281390 (LYLE et al.) 7 September 1988 see examples	1-12
A	Chemical Abstracts, vol. 112, no. 11, 12 March 1990, (Columbus, Ohio, US), S. Flygare et al.: "Magnetic aqueous two-phase separation in preparative applications", see page 606, abstract 96880s, & Enzyme Microb. Technol. 1990, 12(2), 95-103	1-12
A	Chemical Abstracts, vol. 82, no. 18, 5 May 1975, (Columbus, Ohio, US), G. Bitton et al.: "Removal of Escherichia coli bacteriophage T7 by magnetic filtration", see page 278, abstract 115953y, & Water Res. 1974, 8(8), 549-51	1-12
A	Chemical Abstracts, vol. 77, no. 14, 2 October 1972, (Columbus, Ohio, US), J. Warren: "New purification procedure for biological vaccines (adsorption on magnetic iron oxides)", see page 308, abstract 92767w, & Immunization Jap. Encephalitis, Conf. 1969 (Pub. 1971), 152-4	1-12
A	Chemical Abstracts, vol. 95, no. 9, 31 August 1981, (Columbus, Ohio, US); P.A. Munro et al.: "Magnetic seeding to aid recovery of biological precipitates", see pages 394-395, abstract 76474q, & Biotechnol. Lett. 1981, 3(6), 297-302	1-12

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9100212
SA 44598

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 26/06/91. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A- 0162819	27-11-85	AU-A-	3916985	05-09-85
		JP-A-	60210766	23-10-85
		SE-A-	8401125	02-09-85
US-A- 4001197	04-01-77	JP-C-	942629	15-03-79
		JP-A-	51150779	24-12-76
		JP-B-	53019821	23-06-78
US-A- 3470067	30-09-69	None		
BE-A- 686243	28-02-67	None		
WO-A- 8401503	26-04-84	US-A-	4508625	02-04-85
		AU-A-	2205683	04-05-84
		DE-T-	3390261	10-01-85
		EP-A-	0124579	14-11-84
		JP-T-	59501867	08-11-84
		SE-B-	452258	23-11-87
		SE-A-	8403217	15-06-84
		CA-A-	1228053	13-10-87
EP-A- 0281390	07-09-88	AU-A-	1426988	26-09-88
		JP-T-	1502319	17-08-89
		WO-A-	8806633	07-09-88

PATENT COOPERATION TREATY

17 Rec'd PCT/PTO 1 APR 1991

INTERNATIONAL APPLICATION NO. PCT/GB91/00212

07/855,036

To:

United States Patent
and Trademark Office
Washington, D.C.

in its capacity as a designated Office

DATE OF MAILING OF
THIS NOTIFICATION:
05 March 1991 (05.03.91)

From:
The International Bureau of WIPO
1211 Geneva 20
Switzerland

NAME(S) OF APPLICANT(S):

REEVE, Michael, Alan

INTERNATIONAL FILING DATE:

13 February 1991 (13.02.91)

PRIORITY DATE(S) CLAIMED:

13 February 1990 (13.02.90)

DATE OF RECEIPT OF RECORD COPY BY INTERNATIONAL BUREAU:

05 March 1991 (05.03.91)

D. Collier
(Authorized Officer)

P A T E N T C O O P E R A T I O N T R E A T Y

TO:

24 Rec'd PCT/PTO

06 MAR 1992

FROM: the INTERNATIONAL BUREAU of the
WORLD INTELLECTUAL PROPERTY
ORGANIZATIONUnited States Patent
and Trademark Office
Washington, D.C.NOTIFICATION CONCERNING
DOCUMENTS TRANSMITTEDIssued pursuant to PCT
Article 36(3)(a)

(as elected Office)

Date of Mailing:

20 February 1992 (20.02.92)

NOTIFICATION

The International Bureau transmits herewith the following documents and number thereof:

1 (number of) copy(s) of the international preliminary examination report (Article 36(3)(a)).

This notification is sent to the above addressee in its capacity as an elected Office.

THE INTERNATIONAL BUREAU OF THE WORLD INTELLECTUAL PROPERTY ORGANIZATION

Mailing Address:

WIPO
34, chemin des Colombettes
1211 Geneva 20
Switzerland

Authorised Officer:

M. Abidine

INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 91/00212

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵: B 03 C 1/00, C 07 K 3/24, 3/28, C 12 N 1/02, 7/02, 5/00

II. FIELDS SEARCHED

Minimum Documentation Searched ?

Classification System	Classification Symbols
IPC ⁵	B 03 C, C 07 K, C 12 N
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *	

III. DOCUMENTS CONSIDERED TO BE RELEVANT*

Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP, A, 0162819 (PERO et al.) 27 November 1985 see the whole document; in particular page 2, line 25 - page 4, line 31 --	1-4,6-8
X	US, A, 4001197 (MITCHELL et al.) 4 January 1977 see the whole document; especially figure 1; columns 6-8, claims --	1-4,6-8,12
X	US, A, 3470067 (WARREN et al.) 30 September 1969 see the whole document; especially columns 1,2, summary; column 8, claims --	1-4,6-8
X	BE, A, 686243 (PFIZER) 28 February 1967 see the whole document, especially pages 7-8, examples 1,2; pages 14-15, claims --	1-4,6-8
		. / .

* Special categories of cited documents:¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search
20th May 1991

Date of Mailing of this International Search Report

- 8.07.91

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

M. PEIS

M. Peis

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	WO, A, 8401503 (COULTER et al.) 26 April 1984 see the whole document; especially page 7, lines 1-5 --	1-12
A	EP, A, 0281390 (LYLE et al.) 7 September 1988 see examples --	1-12
A	Chemical Abstracts, vol. 112, no. 11, 12 March 1990, (Columbus, Ohio, US), S. Flygare et al.: "Magnetic aqueous two-phase separation in preparative applications", see page 606, abstract 96880s, & Enzyme Microb. Technol. 1990, 12(2), 95-103 --	1-12
A	Chemical Abstracts, vol. 82, no. 18, 5 May 1975, (Columbus, Ohio, US), G. Bitton et al.: "Removal of Escherichia coli bacteriophage T7 by magnetic filtration", see page 278, abstract 115953y, & Water Res. 1974, 8(8), 549-51 --	1-12
A	Chemical Abstracts, vol. 77, no. 14, 2 October 1972, (Columbus, Ohio, US), J. Warren: "New purification procedure for biological vaccines (adsorption on magnetic iron oxides)", see page 308, abstract 92767w, & Immunization Jap. Encephalitis, Conf. 1969 (Pub. 1971), 152-4 --	1-12
A	Chemical Abstracts, vol. 95, no. 9, 31 August 1981, (Columbus, Ohio, US); P.A. Munro et al.: "Magnetic seeding to aid recovery of biological precipitates", see pages 394-395, abstract 76474q, & Biotechnol. Lett. 1981, 3(6), 297-302 -----	1-12

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9100212
SA 44598

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 26/06/91. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A- 0162819	27-11-85	AU-A-	3916985	05-09-85
		JP-A-	60210766	23-10-85
		SE-A-	8401125	02-09-85
US-A- 4001197	04-01-77	JP-C-	942629	15-03-79
		JP-A-	51150779	24-12-76
		JP-B-	53019821	23-06-78
US-A- 3470067	30-09-69	None		
BE-A- 686243	28-02-67	None		
WO-A- 8401503	26-04-84	US-A-	4508625	02-04-85
		AU-A-	2205683	04-05-84
		DE-T-	3390261	10-01-85
		EP-A-	0124579	14-11-84
		JP-T-	59501867	08-11-84
		SE-B-	452258	23-11-87
		SE-A-	8403217	15-06-84
		CA-A-	1228053	13-10-87
EP-A- 0281390	07-09-88	AU-A-	1426988	26-09-88
		JP-T-	1502319	17-08-89
		WO-A-	8806633	07-09-88

REC'D 19 FEB 1992

PATENT COOPERATION TREATY
INTERNATIONAL PRELIMINARY EXAMINATION REPORT

WIPO PCT

IDENTIFICATION OF THE INTERNATIONAL APPLICATION		Applicant's or Agent's File Reference PP/8620																						
International Application No. PCT/GB91/00212	International Filing Date 13 February 1991 (13.02.91)																							
Receiving Office UK PATENT OFFICE	Priority Date Claimed 13 February 1990 (13.02.90)																							
Applicant (Name) AMERSHAM INTERNATIONAL PLC ET AL																								
BASIS OF REPORT																								
<p>1. AMENDMENTS AND/OR RECTIFICATIONS¹ — The amendments and/or rectifications made before this International Preliminary Examining Authority in respect of the claims, the description, and/or drawings in the above-identified international application are annexed to this report.</p> <p>a. <input checked="" type="checkbox"/> This report has been established on the basis of the following application documents:</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; padding-right: 10px;"><input checked="" type="checkbox"/> the application documents as filed</td> <td style="width: 70%;"></td> </tr> <tr> <td><input type="checkbox"/> description, pages</td> <td>as originally filed</td> </tr> <tr> <td><input type="checkbox"/> description, pages</td> <td>filed with your letter of</td> </tr> <tr> <td><input type="checkbox"/> description, pages</td> <td>filed with your letter of</td> </tr> <tr> <td><input type="checkbox"/> description, pages</td> <td>filed with your letter of</td> </tr> <tr> <td><input type="checkbox"/> claim(s)</td> <td>as originally filed</td> </tr> <tr> <td><input type="checkbox"/> claim(s)</td> <td>filed with your letter of</td> </tr> <tr> <td><input type="checkbox"/> claim(s)</td> <td>filed with your letter of</td> </tr> <tr> <td><input type="checkbox"/> claim(s)</td> <td>filed with your letter of</td> </tr> <tr> <td><input type="checkbox"/> drawings, sheet/fig.</td> <td>as originally filed</td> </tr> <tr> <td><input type="checkbox"/> drawings, sheet/fig.</td> <td>filed with your letter of</td> </tr> </table> <p>b. <input type="checkbox"/> The amendments resulted in the cancellation of the following sheets:</p> <p>c. <input type="checkbox"/> This report has been established as if the amendments indicated on the extra sheet have not been made, since, for the reasons indicated, they have been considered to go beyond the disclosure as filed.</p>			<input checked="" type="checkbox"/> the application documents as filed		<input type="checkbox"/> description, pages	as originally filed	<input type="checkbox"/> description, pages	filed with your letter of	<input type="checkbox"/> description, pages	filed with your letter of	<input type="checkbox"/> description, pages	filed with your letter of	<input type="checkbox"/> claim(s)	as originally filed	<input type="checkbox"/> claim(s)	filed with your letter of	<input type="checkbox"/> claim(s)	filed with your letter of	<input type="checkbox"/> claim(s)	filed with your letter of	<input type="checkbox"/> drawings, sheet/fig.	as originally filed	<input type="checkbox"/> drawings, sheet/fig.	filed with your letter of
<input checked="" type="checkbox"/> the application documents as filed																								
<input type="checkbox"/> description, pages	as originally filed																							
<input type="checkbox"/> description, pages	filed with your letter of																							
<input type="checkbox"/> description, pages	filed with your letter of																							
<input type="checkbox"/> description, pages	filed with your letter of																							
<input type="checkbox"/> claim(s)	as originally filed																							
<input type="checkbox"/> claim(s)	filed with your letter of																							
<input type="checkbox"/> claim(s)	filed with your letter of																							
<input type="checkbox"/> claim(s)	filed with your letter of																							
<input type="checkbox"/> drawings, sheet/fig.	as originally filed																							
<input type="checkbox"/> drawings, sheet/fig.	filed with your letter of																							
<p>2. PRIORITY²</p> <p>a. <input type="checkbox"/> This report has been established as if no priority has been claimed due to the failure to furnish within the prescribed time limit the requested:</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; padding-right: 10px;"><input type="checkbox"/> copy of the earlier application whose priority has been claimed.</td> <td style="width: 70%;"></td> </tr> <tr> <td><input type="checkbox"/> translation of the earlier application whose priority has been claimed.</td> <td></td> </tr> </table> <p>b. <input type="checkbox"/> This report has been established as if no priority has been claimed due to the fact that the priority claim has been found invalid.</p>			<input type="checkbox"/> copy of the earlier application whose priority has been claimed.		<input type="checkbox"/> translation of the earlier application whose priority has been claimed.																			
<input type="checkbox"/> copy of the earlier application whose priority has been claimed.																								
<input type="checkbox"/> translation of the earlier application whose priority has been claimed.																								
Thus, for the purposes of this report, the international filing date indicated above is considered to be the relevant date.																								
<p>* Where replacement sheets are annexed to this report, a translation of these replacement sheets must be furnished to the elected Offices within the time limit applicable under PCT Article 39(1).</p>																								

BASIS OF REPORT (Continued)**3. UNITY OF INVENTION³ — The international application does not comply with the requirement of unity of invention.**

a. In response to an invitation to restrict or pay additional fees the applicant has:

- restricted the claims.
- paid additional fees.
- paid additional fees under protest. Where requested by the applicant, the text of the protest together with the decision taken thereon are annexed to this report.
- neither restricted nor paid additional fees.

b. No invitation has been issued. The opinion of this International Preliminary Examining Authority is that the international application does not comply with the requirement of unity of invention for the following reasons. (specify)

c. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- all parts.
- the parts relating to the restricted claims, that is claims Nos. _____
- the parts relating to the main invention, that is claims Nos. _____.

4. NON-ESTABLISHMENT OF REPORT ON QUESTIONS OF NOVELTY, INVENTIVE STEP OR INDUSTRIAL APPLICABILITY⁴

The questions of whether the claimed invention appears to be novel, to involve an inventive step or to be industrially applicable have not for the reasons indicated been gone into in respect of:

a. the entire international application

b. claims Nos. _____

for the following reasons:

Said international application, or said claims Nos. _____ relate to the following subject matter which does not require an international preliminary examination. (specify)

The description, claims, or drawings (indicate particular elements) or said claims Nos. _____ are so unclear that no meaningful opinion could be formed.

The claims, or said claims Nos. _____ are so inadequately supported by the description that no meaningful opinion could be formed.

Said claims Nos. _____ are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all.)³

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵ B03C 1/00: C07K 3/24: 3/28: C12N 1/02. 7/02. 5/00

**REASONED STATEMENT AS TO CLAIMS MEETING CRITERIA OF NOVELTY (N), INVENTIVE STEP (IS)
AND INDUSTRIAL APPLICABILITY (IA)⁶ AND CITATIONS⁷ AND EXPLANATIONS⁸
SUPPORTING SUCH STATEMENT**

CLAIM NUMBER	STATEMENT (CRITERIA)	CITATIONS AND EXPLANATIONS
1-12	YES (N. IS. IA)	<p>All claims meet the requirements of industrial applicability novelty and inventive step.</p> <p>They are distinguished from the documents cited by the International Searching Authority in that there is no disclosure of the suspension of magnetic particles in a polymer solution prior to precipitating the polymer out of the solution.</p>

NON-WRITTEN DISCLOSURES *

Kind of Non-Written Disclosure	Date of Written Disclosure referring to the Non-Written Disclosure	Date of Non-Written Disclosure

CERTAIN PUBLISHED DOCUMENTS †

Application/Patent	Date of Publication	Filing Date	Priority Date (Valid Claim)

CERTAIN DEFECTS IN THE INTERNATIONAL APPLICATION ‡

The following defects in the form or contents of the international application have been noted.

The claims are not in two part form as required by Rule 6.3(b).

CERTAIN OBSERVATIONS ON THE INTERNATIONAL APPLICATION §

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description have been noted.

The contents of the Agent's letter dated 10 September 1991 have been considered.

CERTIFICATION

Date Demand Submitted 10 September 1991 (10.09.01)	Date of Completion of the International Preliminary Examination Report 12 February 1992 (12.02.92)
International Preliminary Examining Authority THE PATENT OFFICE CARDIFF RD., NEWPORT GWENT NP9 1RH	Signature of Authorized Officer J L FREEMAN

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, " with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	WO, A, 8401503 (COULTER et al.) 26 April 1984 see the whole document; especially page 7, lines 1-5 --	1-12
A	EP, A, 0281390 (LYLE et al.) 7 September 1988 see examples --	1-12
A	Chemical Abstracts, vol. 112, no. 11, 12 March 1990, (Columbus, Ohio, US), S. Flygare et al.: "Magnetic aqueous two-phase separation in preparative applications", see page 606, abstract 96880s, & Enzyme Microb. Technol. 1990, 12(2), 95-103 --	1-12
A	Chemical Abstracts, vol. 82, no. 18, 5 May 1975, (Columbus, Ohio, US), G. Bitton et al.: "Removal of Escherichia coli bacteriophage T7 by magnetic filtration", see page 278, abstract 115953y, & Water Res. 1974, 8(8), 549-51 --	1-12
A	Chemical Abstracts, vol. 77, no. 14, 2 October 1972, (Columbus, Ohio, US), J. Warren: "New purification procedure for biological vaccines (adsorption on magnetic iron oxides)", see page 308, abstract 92767w, & Immunization Jap. Encephalitis, Conf. 1969 (Pub. 1971), 152-4 --	1-12
A	Chemical Abstracts, vol. 95, no. 9, 31 August 1981, (Columbus, Ohio, US); P.A. Munro et al.: "Magnetic seeding to aid recovery of biological precipitates", see pages 394-395, abstract 76474q, & Biotechnol. Lett. 1981, 3(6), 297-302 -----	1-12

INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 91/00212

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵: B 03 C 1/00, C 07 K 3/24, 3/28, C 12 N 1/02, 7/02, 5/00

II. FIELDS SEARCHED

Minimum Documentation Searched ?

Classification System	Classification Symbols
IPC ⁵	B 03 C, C 07 K, C 12 N

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

III. DOCUMENTS CONSIDERED TO BE RELEVANT*

Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP, A, 0162819 (PERO et al.) 27 November 1985 see the whole document; in particular page 2, line 25 - page 4, line 31 --	1-4,6-8
X	US, A, 4001197 (MITCHELL et al.) 4 January 1977 see the whole document; especially figure 1; columns 6-8, claims --	1-4,6-8,12
X	US, A, 3470067 (WARREN et al.) 30 September 1969 see the whole document; especially columns 1,2, summary; column 8, claims --	1-4,6-8
X	BE, A, 686243 (PFIZER) 28 February 1967 see the whole document, especially pages 7-8, examples 1,2; pages 14-15, claims --	1-4,6-8
		. / .

* Special categories of cited documents: *0

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

20th May 1991

Date of Mailing of this International Search Report

- 8.07.91

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

M. PEIS

M. Peis

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.GB 9100212
SA 44598

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 26/06/91. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A- 0162819	27-11-85	AU-A-	3916985	05-09-85
		JP-A-	60210766	23-10-85
		SE-A-	8401125	02-09-85
US-A- 4001197	04-01-77	JP-C-	942629	15-03-79
		JP-A-	51150779	24-12-76
		JP-B-	53019821	23-06-78
US-A- 3470067	30-09-69	None		
BE-A- 686243	28-02-67	None		
WO-A- 8401503	26-04-84	US-A-	4508625	02-04-85
		AU-A-	2205683	04-05-84
		DE-T-	3390261	10-01-85
		EP-A-	0124579	14-11-84
		JP-T-	59501867	08-11-84
		SE-B-	452258	23-11-87
		SE-A-	8403217	15-06-84
		CA-A-	1228053	13-10-87
EP-A- 0281390	07-09-88	AU-A-	1426988	26-09-88
		JP-T-	1502319	17-08-89
		WO-A-	8806633	07-09-88




PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :	A1	(11) International Publication Number:	WO 91/12079
B03C 1/00, C07K 3/24, 3/28 C12N 1/02, 7/02, 5/00		(43) International Publication Date:	22 August 1991 (22.08.91)

(21) International Application Number:	PCT/GB91/00212	(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.
(22) International Filing Date:	13 February 1991 (13.02.91)	
(30) Priority data:		
9003253.3	13 February 1990 (13.02.90) GB	
(71) Applicant (for all designated States except US):	AMER-SHAM INTERNATIONAL PLC [GB/GB]; Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA (GB).	
(72) Inventor; and		Published
(75) Inventor/Applicant (for US only) :	REEVE, Michael, Alan [GB/GB]; 149 Grays Road, Henley-on-Thames RG9 1TE (GB).	With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(74) Agent:	PENNANT, Pyers; Stevens, Hewlett & Perkins, 2 Serjeants' Inn, Fleet Street, London EC4Y 1LL (GB).	

(54) Title: METHOD TO ISOLATE MACROMOLECULES USING MAGNETICALLY ATTRACTABLE BEADS WHICH DO NOT SPECIFICALLY BIND THE MACROMOLECULES



(57) Abstract

A method of recovering a biopolymer from solution involves the use of magnetically attractable beads which do not specifically bind the polymer. The beads are suspended in the solution. Then the polymer is precipitated out of solution and becomes non-specifically associated with the beads. When the beads are magnetically drawn down, the polymer is drawn down with them. The polymer can subsequently be resolubilised and separated from the beads.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

A
PR/TS

- 1 -

Method to isolate macromolecules using magnetically attractive beads which do not specifically bind the macromolecules.

5

I Introduction

Many techniques in Molecular Biology, Biochemistry and Chemistry rely upon the process of precipitation. There are two types of precipitation.

In the first type of precipitation, the components from a complex solution that are not of interest are selectively precipitated. The precipitate and supernatant are then separated (usually by centrifugation or filtration) and the supernatant is kept for further use.

In the second type of precipitation, the components of interest from a complex solution are selectively precipitated. The precipitate and supernatant are separated (again by centrifugation or filtration) and the precipitate is kept for further use. This precipitate may well be redissolved for further use.

Examples of precipitation that are of particular relevance to this invention will now be discussed.

a. Alcohol Precipitation of Nucleic Acid Molecules from Solution:

Alcohol precipitation of nucleic acid molecules from solution is a standard procedure for the concentration and/or purification of these species from complex solutions. Typical methods involve the addition of salt (e.g. 0.1 volumes of 2.5 M sodium acetate (pH 5.2)) to a solution containing nucleic acids followed by addition of an alcohol (e.g. 2.5

SEARCHED
SERIALIZED
INDEXED
FILED

- 2 -

volumes of ethanol). The nucleic acids then precipitate. The precipitated nucleic acid molecules aggregate (usually with the aid of reduced temperatures; e.g. 5 minutes on dry ice) and are 5 recovered by centrifugation. After removal of the supernatant, the pelleted precipitate is normally redissolved in the required volume of an appropriate buffer. The nucleic acid may be DNA (partially or wholly single or double stranded), RNA (partially or 10 wholly single or double stranded), mixtures of any of the above or a hybrid RNA/DNA species. The salt used may be sodium acetate, sodium chloride, potassium acetate, potassium chloride, ammonium acetate, ammonium chloride, guanidinium thiocyanate, guanidinium 15 isothiocyanate, guanidinium chloride or mixtures of the above. The alcohol used is normally ethanol or isopropanol.

20 b. Precipitation of Bacteriophage and Other Viruses from Solution:

Precipitation of bacteriophage and other viruses from solution by the addition of solutions containing high concentrations of highly hydratable polymers, such as polyethylene glycol (PEG), and salts, 25 such as sodium chloride, is a standard procedure for the concentration and/or purification of these species from complex solutions. The bacteriophage or other viruses precipitated in this way may be used for nucleic acid extraction, protein extraction, infection of host cells, structural studies or immunological 30 studies. A typical procedure involves the addition of 0.2 volumes of 20% (w/v) PEG in 2.5 M sodium chloride to the complex solution known to contain the bacteriophage or other viruses. The bacteriophage or 35 other viruses precipitate. The precipitated particles

- 3 -

then aggregate (normally with the aid of incubation at reduced temperatures; e.g. 60 minutes at 4°C) and are recovered by centrifugation. After removal of the supernatant, the pellet (comprising precipitated
5 particles of bacteriophage or other viruses) is normally redissolved in the required volume of an appropriate buffer. The bacteriophage may be filamentous (e.g. M13) or complex (e.g. lambda). They may infect bacteria, animal or plant cells and they may
10 be DNA-containing or RNA-containing.

C. Removal of Bacterial DNA, Proteins and Membranes from Bacterial Lysates:

Another type of precipitation of interest to
15 Molecular Biologists is used for the removal of bacterial DNA, proteins and membranes from bacterial lysates containing, in addition to the above, RNA and plasmid DNA and/or cosmid DNA and/or bacteriophage DNA. This forms the basis of the alkaline lysis procedure
20 for preparations of low molecular weight DNA. In this procedure, the bacterial cells (e.g. E.coli) are lysed by treatment with sodium hydroxide (e.g. 200 mM) and the detergent sodium dodecyl sulphate (SDS) (e.g. 0.3-
1.0% (w/v)). Addition of a mixture of either sodium or
25 potassium acetate at low pH (e.g. 0.5 times the volume of lysis buffer of 3 M sodium or potassium acetate adjusted to pH 4.8 with acetic acid) leads to the formation of a precipitate containing protein, membrane fragments and the entrapped bacterial DNA. The RNA and
30 low molecular weight DNA species are not entrapped in this precipitate and can be recovered from the supernatant after centrifugation or filtration of the precipitate. The low molecular weight DNA species can be purified and/or concentrated, along with cellular
35 RNA, by subsequent alcohol precipitation from this supernatant as described above. The DNA species

- 4 -

extracted by this procedure may be plasmid, cosmid or bacteriophage-derived. The volume of cells lysed can be as little as a few microlitres or as large as many litres of bacterial culture.

5

II Description of the Invention

In one aspect this invention provides a method of treating a solution of a polymer by the use of magnetically attractable beads which do not

10 specifically bind the polymer, comprising the steps of:

- suspending the magnetically attractable beads in the solution,

- precipitating the polymer out of solution whereby it becomes non-specifically associated with the

15 beads,

- applying a magnetic field to draw down a precipitate of the beads and the associated polymer, and

20 - separating the precipitate from a supernatant liquid.

The key to the invention is the use of magnetically attractable beads (hereinafter magnetic beads). The nature of the magnetic beads is not critical, and commercially available beads may be used.

25 The beads typically have an average diameter in the range 1 to 100 µm, and comprise finely divided magnetizable material encapsulated in organic polymer.

Or the organic polymer may be omitted. Beads of magnetic iron oxide are commercially available.

30 Such beads have been successfully used in this invention in sizes ranging from below 1 µm up to 40 µm. Even the larger beads remain in suspension at least for the duration of the precipitation step; their subsequent tendency to settle out assists the magnetic field in drawing down the precipitate.

35 To improve recovery of precipitated polymers,

- 5 -

the beads may be pretreated to reduce any unwanted tendency to bind the polymers permanently. For example, when the polymers are nucleic acids, the beads may be pre-treated with a phosphate solution. This 5 treatment is believed to phosphatize any exposed magnetisable material, and may not be necessary if the magnetisable material is completely encapsulated in inert polymer.

The beads are preferably added to the 10 solution either before, or together with, a reagent used to precipitate the polymer. Alternatively, the beads may be added after the precipitation step, under conditions to cause the pre-existing precipitate to become associated with them.

15 The starting solution is preferably aqueous. However starting solutions in polar or non-polar organic solvents are envisaged, particularly when the polymer is of synthetic origin.

While the invention is applicable to polymers 20 generally, it is of particular importance in relation to biopolymers. Biopolymers are polymers found in biological systems. The nature of the biopolymer is not critical to the invention. Biopolymers include nucleic acids (DNA and RNA), proteins, polypeptides, 25 polysaccharides, cell membrane material, bacteriophages, virus, and procaryotic and eucaryotic cells.

At the outset, the polymer or biopolymer is present in solution, the term solution being used 30 broadly to cover permanently stable suspensions in which the polymer molecules are not aggregated.

It is a feature of the invention that the magnetic beads do not specifically bind the polymer. By this feature, the present invention is distinguished 35 from many prior techniques which involve providing a coating on the surface of magnetic beads designed to

- 6 -

specifically bind the substance to be drawn down out of solution. When the polymer is precipitated out of solution in the presence of the suspended magnetic beads, it becomes non-specifically associated with the 5 beads. When the beads are drawn down by an applied magnetic field, the associated precipitated polymer is drawn down with them. But when in solution, the polymer does not become associated with the beads.

When the solute is of more interest than the 10 solvent, the method may be used either to concentrate an initially dilute solution, or to recover one or more polymers from a mixture of polymers, or for both these purposes in sequence. For a sequence of manipulations, the same beads can conveniently be used. The nature of 15 the liquids used to dissolve or re-dissolve the polymer, and of reagents used to precipitate polymer, are not material to this invention. A skilled reader will have no difficulty in choosing liquids and reagents appropriate to his needs.

20 In another aspect, the invention provides an automated device for performing this method, which device comprises an automated pipettor and a magnet which may be a permanent magnet or an electromagnet.

The invention will now be discussed with 25 reference to the three types of precipitation given in the introduction.

a. Alcohol Precipitation of Nucleic Acid Molecules from Solution:

30 Magnetic bead induced precipitate separation can be used to greatly improve the process of alcohol precipitation of nucleic acids. The alcohol precipitation procedure as modified by this invention is shown in Figure 1a. Magnetic beads are added to the 35 nucleic acid in solution. Salt is then added (the magnetic beads can also be added at the same time as

- 7 -

the salt). The nucleic acid is still soluble at this stage. Alcohol is then added. This causes the nucleic acid to come out of solution. The precipitated nucleic acid aggregates around the suspended magnetic beads

5 (which may well act as nucleation sites for this aggregation process). The aggregation stage may be assisted for some types of precipitations by chilling (though chilling does not appear to be necessary for simple precautions of plasmid, phage DNA, RNA and

10 genomic DNA by this method). A magnetic field is then applied to the precipitation. This magnetic field is used to draw the complex of magnetic beads and precipitated nucleic acid to the bottom (or side) of the tube. The supernatant is then removed from the

15 tube. At this point, the precipitate can be washed with ethanol, and/or isopropanol and/or 70% (v/v) ethanol to remove any residual salt, nucleotides, chemicals or organic solvents remaining from treatments of the nucleic acid prior to the precipitation step.

20 The nucleic acid is insoluble in isopropanol, ethanol and 70% (v/v) ethanol. The nucleic acid therefore remains aggregated around the magnetic beads during washing. The washing step can thus be performed vigorously (e.g. by vortex mixing) without risk of losing the precipitate. After the washing step, if

25 performed, the precipitate is redissolved in the required volume of an appropriate buffer in the absence of the magnetic field. Reapplication of the magnetic field to the tube results in just the magnetic beads

30 being drawn to the bottom (or side) of the tube (as the nucleic acid is now dissolved rather than a precipitate as before). The redissolved nucleic acid can now be separated from the magnetic beads by collecting the supernatant containing the dissolved nucleic acid with

35 a pipette whilst the beads are held against the bottom (or side) of the tube by the magnetic field.

The modification of alcohol precipitation by this invention has several clear advantages over the conventional method of precipitation using centrifugation. The procedure, as modified by this 5 invention, is:

1. Faster (the modified procedure takes only 1-2 minutes, as opposed to 10-30 minutes for the conventional procedure using centrifugation).
2. Not reliant upon centrifugation equipment.
- 10 3. Readily suited to automation (a great many tubes could be placed over a large electromagnet and these could all be alcohol precipitated simultaneously using a multi channel pipetting device).
4. Especially effective if the precipitate of 15 nucleic acid is to be washed with isopropanol, ethanol or 70% ethanol (e.g. to remove any residual salt, nucleotides or organic solvents such as phenol). Washing can be performed rapidly with no risk of loss of material as can occur with the conventional method based upon centrifugation (where the pellet often 20 detaches from the bottom of the tube during such washing).

Magnetic bead induced precipitate separation can also be used to greatly improve the process of 25 deproteinization and alcohol precipitation of nucleic acids. The deproteinization and alcohol precipitation procedure as modified by this invention is shown in Figure 1b. DNA is given as the example in Figure 4b, though the process is equally applicable to any type of 30 nucleic acid. Magnetic beads are added to the protein and nucleic acid in solution. Salt is then added (the magnetic beads can also be added at the same time as the salt). The protein and nucleic acid are still soluble at this stage. Alcohol is then added. This 35 causes the protein and nucleic acid to come out of solution. The precipitated protein and nucleic acid

- 9 -

aggregate around the suspended magnetic beads (which may well act as nucleation sites for this aggregation process). The aggregation stage may be assisted for some types of precipitations by chilling (though 5 chilling does not appear to be necessary for simple precipitations of plasmid, phage DNA, RNA and genomic DNA with protein extraction by this method). A magnetic field is then applied to the precipitation. This magnetic field is used to draw the complex of 10 magnetic beads and precipitated protein and nucleic acid to the bottom (or side) of the tube. The supernatant is then removed from the tube. The protein and nucleic acid remain aggregated around the magnetic beads. Phenol and/or phenol/chloroform and/or 15 phenol/ethanol is then added and the magnetic beads resuspended in the absence of the magnetic field. This resuspension extracts the precipitated protein from the magnetic beads whilst the nucleic acid remains still attached. A magnetic field is again applied to the 20 tube. This magnetic field is used to draw the complex of precipitated nucleic acid and magnetic beads to the bottom (or side) of the tube. The phenolic supernatant (containing the extracted protein) is then removed from the tube. At this point, the precipitate can be washed 25 with ethanol, and/or isopropanol and/or 70% (v/v) ethanol to remove any residual salt, nucleotides, chemicals or organic solvents remaining. The nucleic acid is insoluble in isopropanol, ethanol and 70% (v/v) ethanol. The nucleic acid therefore remains aggregated 30 around the magnetic beads during washing. The washing step can thus be performed vigorously (e.g. by vortex mixing) without risk of losing the precipitate. After the washing step, if performed, the precipitate is redissolved in the required volume of an appropriate 35 buffer in the absence of the magnetic field.

Reapplication of the magnetic field to the tube results

- 10 -

in just the magnetic beads being drawn to the bottom (or side) of the tube (as the nucleic acid is now dissolved rather than a precipitate as before). The redissolved nucleic acid can now be separated from the 5 magnetic beads by collecting the supernatant containing the dissolved nucleic acid with a pipette whilst the beads are held against the bottom (or side) of the tube by the magnetic field.

The modification of deproteinization and 10 alcohol precipitation by this invention has several clear advantages over the conventional method of using centrifugation. The procedure, as modified by this invention, is:

1. Faster (the modified procedure takes only 5-15 minutes, as opposed to 20-40 minutes for the conventional procedure using centrifugation).
2. Not reliant upon centrifugation equipment.
3. Readily suited to automation (a great many tubes could be placed over a large electromagnet and 20 these could all be deproteinized and alcohol precipitated simultaneously using a multi channel pipetting device).
4. Especially effective if the precipitate of nucleic acid is to be washed with isopropanol, ethanol or 70% ethanol (e.g. to remove any residual salt, nucleotides or organic solvents such as phenol). Washing can be performed rapidly with no risk of loss of material as can occur with the conventional method based upon centrifugation (where the pellet often 25 detaches from the bottom of the tube during such washing).

b. Precipitation of Bacteriophage and Other Viruses from Solution:

35 Magnetic bead induced precipitate separation can be used to greatly improve the process of

- 11 -

hydrateable polymer/salt precipitation of bacteriophage and other viruses. The hydrateable polymer/salt precipitation procedure as modified by this invention is shown in Figure 2. Magnetic beads, hydrateable polymer (e.g. PEG) and salt (e.g. sodium chloride) are added to the bacteriophage or other viral particles in solution. This causes the particles of bacteriophage or other viruses to come out of solution. The precipitated particles aggregate round the suspended magnetic beads (which may well act as nucleation sites for this aggregation process). The aggregation stage may be assisted for some types of precipitations by chilling (though chilling does not appear to be necessary for simple precipitations of bacteriophage). A magnetic field is then applied to the precipitation. This magnetic field is used to draw the complex of magnetic beads and precipitated particles to the bottom (or side) of the tube. The supernatant is then removed from the tube. The precipitate is redissolved in the required volume of an appropriate buffer in the absence of the magnetic field. Reapplication of the magnetic field to the tube results in just the magnetic beads being drawn to the bottom (or side) of the tube (as the particles of bacteriophage or other viruses are now dissolved rather than a precipitate is before). The redissolved particles of bacteriophage or other viruses can now be separated from the magnetic beads by collecting the supernatant containing the dissolved particles with a pipette whilst the beads are held against the bottom (or side) of the tube by the magnetic field.

The modification of hydrateable polymer/salt precipitation by this invention has several clear advantages over the conventional method of precipitation using centrifugation. The procedure, as modified by this invention, is:

- 12 -

1. Faster (the modified procedure takes only 1-2 minutes, as opposed to 65-75 minutes for the conventional procedure using centrifugation).
2. Not reliant upon centrifugation equipment.
- 5 3. Readily suited to automation (a great many tubes could be placed over a large electromagnet and these could all be hydrateable polymer/salt precipitated simultaneously using a multi channel pipetting device).
- 10 4. Less likely to produce aerosols of bacteriophage and other viruses than the conventional procedure based upon centrifugation. This is safer if the bacteriophage or other viruses are harmful and will result in less airborne microbial contamination in the laboratory.
- 15

c. Removal of Bacterial DNA, Proteins and Membranes from Bacterial Lysates:

Magnetic bead induced precipitate separation can also be used to greatly improve the precipitation of bacterial DNA, membranes and proteins from bacterial lysates containing RNA and low molecular weight DNA species. The preparation of RNA and low molecular weight DNA species as modified by this invention is shown in Figure 3. Bacteria (containing the low molecular weight DNA species of interest) are lysed with a mixture of sodium hydroxide and SDS. This releases bacterial DNA, proteins, membranes, RNA and low molecular weight DNA into solution. Magnetic beads and either sodium or potassium acetate are then added at low pH. This causes the SDS, proteins and membranes to precipitate. The precipitate also entraps the bacterial DNA and the magnetic beads. A magnetic field is then applied to the precipitation. This magnetic field is used to draw the complex of magnetic beads and precipitated material to the bottom (or side) of the

- 13 -

tube. The supernatant is then removed from the tube with a pipette whilst the complex of beads and precipitated material is held against the bottom (or side) of the tube by the magnetic field. The low 5 molecular weight DNA can be purified and/or concentrated from this supernatant (along with any remaining cellular RNA that will also be purified) by alcohol precipitation as described above.

The modification of low molecular weight DNA 10 preparation by this invention has several clear advantages over the conventional method of precipitation using centrifugation. The procedure, as modified by this invention, is:

1. Faster (the modified procedure takes only 5-10 15 minutes, as opposed to 30-60 minutes for the conventional procedure using centrifugation).
2. Not reliant upon centrifugation equipment.
3. Readily suited to automation (a great many tubes could be placed over a large electromagnet and 20 these could all be precipitated simultaneously using a multi channel pipetting device).

d. DNA Preparation from Bacteriophage or Other Viruses:

Magnetic bead induced precipitate separation 25 has been shown to greatly improve the process of hydrateable polymer/salt precipitation of bacteriophage and other viruses. The hydrateable polymer/salt precipitation has been shown in Figure 2. Magnetic 30 bead induced precipitate separation has also been shown to greatly improve the precipitation of bacterial DNA, membranes and proteins from bacterial lysates containing RNA and low molecular weight DNA species. The preparation of RNA and low molecular weight DNA 35 species as modified by this invention has been shown in Figure 3. The combination of these two procedures can

- 14 -

be used to derive a novel procedure for the purification of low molecular weight DNA from bacteriophage or other viral particles. In this novel procedure, particles of bacteriophage or other viruses are precipitated using the magnetic bead method given in Figure 3. The purified particles are then subjected to lysis by sodium hydroxide and SDS. This step separates the coat proteins from the DNA, with both being released into solution. Magnetic beads and either sodium or potassium acetate are then added at low pH. This causes the SDS and coat proteins to precipitate. The precipitate also entraps the magnetic beads. A magnetic field is then applied to the precipitation. This magnetic field is used to draw the complex of magnetic beads and precipitated material to the bottom (or side) of the tube. The supernatant is then removed from the tube with a pipette whilst the complex of beads and precipitated material is held against the bottom (or side) of the tube by the magnetic field. The low molecular weight DNA can be purified and/or concentrated from this supernatant by alcohol precipitation as described above. The modification of low molecular weight DNA preparation from bacteriophage or other viruses by this invention has several clear advantages over the conventional method of precipitation using centrifugation and other methods. The procedure, as modified by this invention, is:

1. Faster (the modified procedure takes only 5-10 minutes, as opposed to 2-3 hours for the conventional procedure using centrifugation).
2. Not reliant upon centrifugation equipment.
3. Readily suited to automation (a great many tubes could be placed over a large electromagnet and these could all be precipitated simultaneously using a multi channel pipetting device).

- 15 -

4. Not reliant upon organic solvent extraction (e.g. by phenol).
5. Less likely to produce aerosols of bacteriophage and other viruses than the conventional procedure based upon centrifugation. This is safer if the bacteriophage or other viruses are harmful and will result in less airborne microbial contamination in the laboratory.
6. Especially effective if the precipitate of nucleic acid is to be washed with isopropanol, ethanol or 70% ethanol. Washing can be performed rapidly with no risk of loss of material as can occur with the conventional method based upon centrifugation (where the pellet often detaches from the bottom of the tube during such washing).

e. Precipitation of Bacteria from Solution

Magnetic bead induced precipitate separation can also be used to effect a novel process of alcohol precipitation of cells e.g. bacterial cells. Magnetic beads are added to the bacteria in solution. Salt is then added (the magnetic beads can also be added at the same time as the salt). The bacteria are still soluble at this stage. Alcohol is then added. This causes the bacteria to come out of solution. The precipitated bacteria aggregate around the suspended magnetic beads (which may well act as nucleation sites for this aggregation process). A magnetic field is then applied to the precipitation. This magnetic field is used to draw the complex of magnetic beads and precipitated bacteria to the bottom (or side) of the tube. The supernatant is then removed from the tube. The precipitate is dissolved in the required volume of an appropriate buffer in the absence of the magnetic field. Reapplication of the magnetic field to the tube results in just the magnetic beads being drawn to the

- 16 -

bottom (or side) of the tube (as the bacteria are now dissolved rather than a precipitate as before). The redissolved bacteria can now be separated from the magnetic beads by collecting the supernatant containing 5 the dissolved bacteria with a pipette whilst the beads are held against the bottom (or side) of the tube by the magnetic field.

Alternatively the bacteria can be lysed directly on the beads as described in IIIC for DNA 10 preparation. The procedure as effected by this invention is:

1. Faster (the modified procedure takes only 1-2 minutes, as opposed to 5-15 minutes for the conventional procedure using centrifugation).
- 15 2. Not reliant upon centrifugation equipment.
3. Readily suited for automation (a great many culture tubes could be placed over a large electromagnet and these could all be alcohol precipitated simultaneously using a multi channel 20 pipetting device).

III Reduction of the Invention to Practice:

The magnetic beads used were cellulose/ferric oxide (50/50), with a particle size of 1-10 microns 25 diameter. Beads were pretreated by soaking in 100 mM tetrasodium pyrophosphate solution, and stored at 4 degrees in 0.1% (w/v) sodium azide at a concentration of 50 mg/ml.

- 30 a. An Example of Alcohol Precipitation of Nucleic Acid Using Magnetic Bead Induced Precipitate Separation:

Example 1

Precipitations of plasmid (e.g. pBR322) can 35 be performed according to the following protocol: Take pBR322 DNA in, for example, 100 µl of TE buffer (10 mM

- 17 -

Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0)); add 1/10th volume (i.e. 10 µl) of a solution containing magnetic beads at 50 mg/ml and tRNA at 1 mg/ml (as carrier, this may be omitted if the concentration of nucleic acid is
5 greater than about 10-25 µg/ml) in 2.5 M sodium acetate adjusted to pH 5.2 with acetic acid; mix; add 2.5 volumes (i.e. 250 µl) of ethanol; mix; place over a permanent magnet to bring down the precipitate; remove the supernatant; wash the pellet in, for example,
10 100 µl of 70% (v/v) ethanol by resuspending with a pipette in the absence of the magnetic field, finally removing the supernatant (wash solution) with a pipette in the presence of the magnetic field; redissolve the pellet in the required volume of TE buffer.

15 No loss occurs on omission of the chilling step for pBR322 DNA. Also, no loss occurs from washing the precipitate with 70% (v/v) ethanol for pBR322 DNA. The above procedure works equally well for human genomic DNA and for RNA.

20

Example 2

Precipitation of pBR322 plasmid DNA with deproteinization can be performed according to the following protocol: Take, for example, pBR322 DNA in
25 20 µl of TE buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0)) containing protein (e.g. a 1/4 dilution of Rainbow MarkersTM (Amersham International)); add 1/10th volume (i.e. 2 µl) of a solution containing magnetic beads at 50 mg/ml and tRNA at 1 mg/ml (as carrier, this may be omitted if the concentration of nucleic acid is greater than about 10-25 µg/ml) in 2.5 M sodium acetate adjusted to pH 5.2 with acetic acid; mix; add 2.5 volumes (i.e. 50 µl) of ethanol; mix; place over a permanent magnet to bring down the
30 precipitate; remove the supernatant; wash the pellet in, for example, 50 µl of phenol (or greater than 60%

- 18 -

(v/v) phenol in ethanol) by resuspending with a pipette in the absence of the magnetic field, finally removing the supernatant (wash solution) with a pipette in the presence of the magnetic field; redissolve the pellet 5 in the required volume of TE buffer. The yield of DNA falls off with less than 40% (v/v) phenol in ethanol used for protein extraction. No losses are incurred with this additional step of protein extraction compared to a protein-free ethanol precipitation.

10 Ethanol precipitation from a solution heavily contaminated with protein is also seen to be dependent upon the extraction of the contaminating protein by a phenol containing solution (i.e. the DNA cannot be redissolved from the beads if protein extraction has

15 not been performed). The successful extraction of the protein into the phenolic layer by this procedure can clearly be seen when using coloured proteins. The above procedure works equally well for human genomic DNA and for RNA.

20

b. An Example of Hydrateable Polymer/Salt Precipitation of Bacteriophage Using Magnetic Bead Induced Precipitate Separation:

25 Example 3

Precipitations can be performed on, for example, 1 ml samples of M13mp8 bacteriophage in 2xTY broth (precleared of bacteria by centrifugation) according to the following protocol: Add 0.4 volumes 30 (i.e. 400 µl) of 2 mg/ml magnetic beads in 20% (w/v) PEG, 2.5 M NaCl; mix; bring down magnetic beads and precipitate using a permanent magnet; redissolve magnetic bead pellet in the required volume of TE buffer.

35 At 0.4 volumes, the amount of bacteriophage not brought down by the beads is negligible.

- 19 -

Example 4

DNA preparations can be performed on, for example, 1 ml samples of M13mp8 bacteriophage in 2xTY broth (precleared of bacteria by centrifugation) according to the following protocol: Add 0.4 volumes (i.e. 400 µl) of 2 mg/ml magnetic beads in 20% (w/v) PEG, 2.5 M NaCl; mix; bring down magnetic beads and precipitate using a permanent magnet; redissolve magnetic bead pellet in 1/5th volume (i.e. 200 µl) of TE buffer; extract with an equal volume (i.e. 200 µl) of phenol; remove aqueous (top) layer; add 1/10th volume (i.e. 20 µl) of a solution containing magnetic beads at 50 mg/ml and tRNA at 1 mg/ml (as carrier, this may be omitted if the concentration of nucleic acid is greater than about 10-25 µg/ml) in 2.5 M sodium acetate adjusted to pH 5.2 with acetic acid; mix; add 2.5 volumes (i.e. 500 µl) of ethanol; mix; place over a permanent magnet to bring down the precipitate; remove the supernatant; wash the pellet in, for example, 100 µl of 70% (v/v) ethanol by resuspending with a pipette in the absence of the magnetic field, finally removing the supernatant (wash solution) with a pipette in the presence of the magnetic field; redissolve DNA in the required volume of TE buffer.

25

Example 5

DNA preparations can also be performed on, for example, 1 ml samples of M13mp8 bacteriophage in 2xTY broth (precleared of bacteria by centrifugation) according to the following protocol: Add 0.4 volumes (i.e. 400 µl) of 2 mg/ml magnetic beads in 20% (w/v) PEG, 2.5 M NaCl; mix; bring down magnetic beads and precipitate using a permanent magnet; redissolve magnetic bead pellet in 1/10th original volume (i.e. 100 µl) of 4 M sodium perchlorate in TE buffer; now

- 20 -

add 2.5 volumes (i.e. 250 µl) of ethanol; mix; place over a permanent magnet to bring down the precipitate; remove the supernatant; wash the pellet twice in, for example, 100 µl of 70% (v/v) ethanol by resuspending
5 with a pipette in the absence of the magnetic field, finally removing the supernatant (wash solution) with a pipette in the presence of the magnetic field; redissolve DNA in the required volume of TE buffer.

10 c. An Example of the Removal of Bacterial DNA.

Proteins and Membranes from Bacterial Lysates Using Magnetic Bead Induced Precipitate Separation:

Example 6

15 pUC19 DNA can be extracted from E.coli MC1061 cells by the following protocol: Take, for example, 250 µl of bacterial culture; add 1/5th volume (i.e. 50 µl) of 1.2 M NaOH, 1.2% (w/v) SDS; mix; incubate 2 minutes at room temperature; now add 3/5th volume
20 (i.e. 150 µl) of 10 mg/ml magnetic beads in 3 M potassium acetate adjusted to pH 4.8 with acetic acid; mix; bring down precipitated material with a permanent magnet and keep supernatant; isopropanol precipitate the supernatant as follows: add 1/10th supernatant
25 volume (i.e. 45 µl) of a solution containing magnetic beads at 50 mg/ml and tRNA at 1 mg/ml (as carrier, this may be omitted if the concentration of nucleic acid is greater than about 10-25 µg/ml) in 2.5 M sodium acetate adjusted to pH 5.2 with acetic acid; mix; add 0.6
30 supernatant volumes (i.e. 270 µl) of isopropanol; mix; place over a permanent magnet to bring down the precipitate; remove the supernatant; wash the pellet in, for example, 100 µl of 70% (v/v) ethanol by resuspending with a pipette in the absence of the
35 magnetic field, finally removing the supernatant (wash solution) with a pipette in the presence of the

- 21 -

magnetic field; redissolve DNA in the required volume of TE buffer. Preparations can be incubated with 10 µg/ml ribonuclease A for 10 minutes at 37°C before analysis.

5

Example 7

pUC19 DNA can also be extracted from E.coli MC1061 cells by the following protocol: Take, for example, 500 µl of bacterial culture; add 1 volume 10 (i.e. 500 µl) of a solution containing magnetic beads at 5 mg/ml in 0.2 M sodium acetate (adjusted to pH 5.2 with acetic acid) dissolved in ethanol; mix; bring down precipitated bacteria with a permanent magnet; remove supernatant and discard; redissolve bacterial 15 pellet in, for example, 300 µl of 0.2 M NaOH, 0.2% (w/v) SDS; mix; incubate 2 minutes at room temperature; now add 1/2 volume (i.e. 150 µl) of 3 M potassium acetate adjusted to pH 4.8 with acetic acid; mix; bring down precipitated material with a permanent 20 magnet and keep supernatant; isopropanol precipitate the supernatant as follows: add 1/10th supernatant volume (i.e. 45 µl) of a solution containing magnetic beads at 50 mg/ml and tRNA at 1 mg/ml (as carrier, this may be omitted if the concentration of nucleic acid is 25 greater than about 10-25 µg/ml) in 2.5 M sodium acetate adjusted to pH 5.2 with acetic acid; mix; add 0.6 supernatant volumes (i.e. 270 µl) of isopropanol; mix; place over a permanent magnet to bring down the precipitate; remove the supernatant; wash the pellet 30 in, for example, 100 µl of 70% (v/v) ethanol by resuspending with a pipette in the absence of the magnetic field, finally removing the supernatant (wash solution) with a pipette in the presence of the magnetic field; redissolve DNA in the required volume 35 of TE buffer. Preparations can be incubated with 10 µg/ml ribonuclease A for 10 minutes at 37°C before

- 22 -

analysis.

- d. An Example of DNA Extraction from Bacteriophage Using Magnetic Bead Induced Precipitate Separation
5 for: Hydrateable Polymer/Salt Precipitation, Removal of Coat Proteins and Alcohol Precipitation of the DNA:

Example 8

10 M13mp8 phage can be precipitated with magnetic beads, PEG and NaCl as described in IIIb. DNA can then be prepared by the alkaline lysis procedure as described in IIIC (dissolving the PEG/NaCl/magnetic beads precipitate of bacteriophage particles in, for 15 example, 250 µl of TE buffer for alkaline lysis). The alkaline lysis method gives M13mp8 DNA at about half the yield of the phenol extraction preparation.

IV Other Types of Precipitation:

20 These include the following:

Precipitations of bacteria, tissue culture cells and blood cells by suitable precipitants (e.g. an equal volume of ethanolic 0.2 M sodium acetate adjusted to pH 5.2 with acetic acid for E.coli) and magnetic 25 bead induced precipitate separation.

Ammonium sulphate precipitation of proteins with magnetic bead induced precipitate separation.

Precipitation of proteins by salts other than ammonium sulphate and magnetic bead induced precipitate 30 separation (e.g. sodium perchlorate, sodium iodide, guanidinium chloride, guanidinium thiocyanate, guanidinium isothiocyanate and other chaotropic agents).

Precipitation of proteins by denaturants and 35 magnetic bead induced precipitate separation.

Precipitation of proteins by detergents and

- 23 -

magnetic bead induced precipitate separation.

Precipitation of nucleic acids by the detergent cetyl trimethyl ammonium bromide and magnetic bead induced precipitate separation.

5 Precipitation or proteins and/or nucleic acids with agents such as trichloroacetic acid (that denature due to extremes of pH) and magnetic bead induced precipitate separation.

10 Selective RNA precipitations from lithium chloride and magnetic bead induced precipitate separation.

15 Selective precipitations of nucleic acids from other nucleic acids (e.g. precipitations of high molecular weight DNA from oligodeoxyribonucleotides and/or deoxynucleotide polyphosphates) which may work better using magnetic bead induced precipitate separation than centrifugation.

Immune precipitations and magnetic bead induced precipitate separation.

20 Complement fixation precipitations and magnetic bead induced precipitate separation.

Blood clotting precipitations and magnetic bead induced precipitate separation.

25 Latex bead precipitation assays and magnetic bead induced precipitate separation.

Haemagglutination assays and magnetic bead induced precipitate separation.

30

35

CLAIMS

5

1. A method of treating a solution of a polymer by the use of magnetically attractable beads which do not specifically bind the polymer, comprising the steps of:

- 10 - suspending the magnetically attractable beads in the solution,
 - precipitating the polymer out of solution whereby it becomes non-specifically associated with the beads,
15 - applying a magnetic field to draw down a precipitate of the beads and the associated polymer, and
 - separating the precipitate from a supernatant liquid.

20 2. A method as claimed in Claim 1, comprising the additional steps of:

- 25 - adding liquid to the precipitate to re-dissolve the polymer and re-suspend the beads.
 - applying a magnetic field to draw down the beads, and
 - separating a supernatant liquid containing the polymer from the beads.

3. A method as claimed in Claim 1 or Claim 2, wherein the solution is in an aqueous medium.

30 4. A method as claimed in any one of Claims 1 to 3, wherein the polymer is a biopolymer.

5. A method as claimed in Claim 1 or Claim 2, wherein the biopolymer is nucleic acid.

35 6. A method as claimed in Claim 4, wherein the biopolymer precipitated comprises protein as well as nucleic acid.

- 25 -

7. A method as claimed in Claim 6, comprising the additional steps of:

- adding liquid to the precipitate to selectively re-dissolve the protein and re-suspend the
5 beads,

- applying a magnetic field to draw down a precipitate of the beads and the associated nucleic acid,

10 - separating a supernatant liquid containing the protein from the precipitate,

- adding liquid to the precipitate to redissolve the nucleic acid and re-suspend the beads,

- applying a magnetic field to draw down the
beads, and

15 - separating a supernatant liquid containing the nucleic acid from the beads.

8. A method as claimed in Claim 4, wherein the biopolymer is bacteriophage and/or virus and/or cell.

9. A method as claimed in Claim 4, wherein the
20 starting solution comprises a mixture of similar biopolymers, one of which is selectively precipitated out of solution in the presence of the beads.

10. A method as claimed in Claim 9, wherein the starting solution is a cell lysate comprising protein,
25 membrane, bacterial DNA and low molecular weight nucleic acids, and the biopolymer precipitated out of solution comprises the protein, membrane and bacterial DNA but not the low molecular weight nucleic acids.

11. A method for recovering low molecular weight
30 nucleic acids from a starting solution of bacteriophage and/or virus, which method comprises the steps:-

- precipitating the bacteriophage and/or virus and/or cell by the method of Claim 8,

- lysing the bacteriophage and/or virus to
35 form a cell lysate solution, and

- treating the cell lysate solution by the

- 26 -

method of Claim 10.

12. An automated device for performing the method of any one of Claims 1 to 11, which device comprises an automated pipettor and a magnet.

5

10

15



20

25

30

35

1/4

FIG. 1a MAGNETIC BEADS ALCOHOL PRECIPITATION






FIG. 2 MAGNETIC BEADS PRECIPITATION OF PHAGE AND VIRUSES



4/4

FIG. 3. MAGNETIC BEADS PRECIPITATION IN DNA MINIPREPS

